Millennium Management
SGMO

Millennium Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Millennium Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-200,000
Closed -$2.84M – 4229
2018
Q2 		$2.84M Hold
200,000
– – ﹤0.01% 2174
2018
Q1 		$3.8M Buy
+200,000
New +$4.28M 0.01% 1971
2015
Q2 		– Sell
-50,000
Closed -$784K – 3784
2015
Q1 		$784K Buy
+50,000
New +$774K ﹤0.01% 2462

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Millennium Management's SGMO Position: Q1 2026 in Review

Millennium Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2026, closing a stake of 37,703 shares — an estimated $15.8K sold.

Millennium Management first reported a position in SGMO in Q2 2013 and held it in 44 quarters. The position peaked at $15.4M in Q4 2015. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Millennium Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2026 after selling out during the quarter.
  • Millennium Management sold 37,703 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $15.8K.
  • Millennium Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 44 quarters.
  • Millennium Management's SANGAMO THERAPEUTICS INC position peaked at $15.4M in Q4 2015.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.